文献速递主动脉疾病

腹主动脉瘤腔内修复术辅助支架置入的结局分析

Outcomes of Endovascular Aneurysm Repair with Adjunctive Stenting.
PubMed 文献 · Ann Vasc Surg · 2021-10-20

本研究基于Cerner HealthFacts数据库(2008-2017)比较了辅助支架置入的EVAR(EVAR-S)与标准EVAR的结局。共纳入4,957例患者(EVAR 3,816例,EVAR-S 1,141例),EVAR-S组合并症评分更高,且与血管并发症、延长住院、30天再入院、心脏事件、呼吸并发症和肾衰竭风险增加相关。结论提示辅助支架置入是病情更复杂、合并症更多的标志,可考虑分期手术或非手术策略。

要点

  • EVAR-S与更高的血管并发症(如需溶栓/经皮血栓清除)相关,但总体发生率低。
  • EVAR-S与延长住院、30天再入院、主要不良心脏事件、呼吸并发症和肾衰竭风险增加独立相关。
  • 辅助支架置入提示患者整体病情更重、更复杂,应考虑分期手术或非手术策略。

核心结论

  • EVAR-S与需要再干预的血管并发症相关,但总体发生率很低。
  • EVAR-S与30天再入院、心脏并发症、呼吸问题和肾衰竭风险增加相关。
  • 辅助支架置入是整体病情更重、更复杂人群的标志,不仅限于血管并发症。

研究设计与样本

  • 回顾性队列研究,使用Cerner HealthFacts数据库(2008-2017)数据。
  • 通过ICD-9诊断和操作代码筛选接受EVAR伴支架(EVAR-S)和不伴支架(EVAR)的患者。
  • 共纳入4,957例患者,其中EVAR 3,816例,EVAR-S 1,141例。
  • 采用卡方分析和多变量 logistic 回归评估患者特征与医学和血管结局的关联。

主要发现

  • EVAR-S组Charlson合并症评分高于EVAR组(2.35 vs. 2.13,P=0.0001)。
  • EVAR-S组溶栓/经皮血栓清除发生率高于EVAR组(0.9% vs. 0.2%,P<0.0004)。
  • EVAR与EVAR-S在穿刺点并发症方面无差异。
  • 多变量分析显示EVAR-S与延长住院(OR 1.37,95%CI 1.03-1.82)独立相关。
  • EVAR-S与30天再入院(OR 1.36,95%CI 1.11-1.68)、主要不良心脏事件(OR 1.59,95%CI 1.09-2.32)、呼吸并发症(OR 1.47,95%CI 1.16-1.88)和肾衰竭(OR 1.57,95%CI 1.16-2.11)独立相关。

临床怎么用

  • 对于需要辅助支架置入的EVAR患者,应认识到其整体病情更复杂,需更全面评估合并症和围手术期风险。
  • 可考虑将手术分期进行,以分散手术风险。
  • 在高风险患者中,若手术风险超过动脉瘤破裂风险,应与患者讨论非手术策略。

局限性

  • 回顾性研究设计,可能存在选择偏倚和混杂因素。
  • 使用行政数据库和ICD-9代码识别患者和结局,可能存在编码错误或遗漏。
  • 缺乏关于支架置入具体适应证和解剖特征的详细信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Endovascular aneurysm repair is the standard of care for abdominal aortic aneurysm repair, however data regarding adjunctive stenting at the time of endovascular aneurysm repair (EVAR) are limited. The study aims to evaluate outcomes of patients undergoing EVAR with and without adjunctive stenting. METHODS: Patients undergoing EVAR with stenting (EVAR-S) and without stenting (EVAR) (2008 - 2017) were selected from Cerner HealthFacts database using ICD-9 diagnosis and procedure codes. Chi-square analysis and multivariable logistic regression were used to evaluate the association of patient characteristics with medical and vascular outcomes. RESULTS: 4,957 patients undergoing EVAR procedures were identified (3,816 EVAR and 1,141 EVAR-S). Demographic analysis revealed that patients who underwent EVAR-S had higher Charlson comorbidity scores (2.35 vs. 2.13, P = 0.0001). EVAR-S was associated with a greater frequency of vascular complications such as thrombolysis/percutaneous thrombectomy (0.9% vs. 0.2%; P < 0.0004). There were no differences seen in access complications between EVAR and EVAR-S. Multivariable analysis revealed that EVAR-S was associated with prolonged length of stay (OR 1.37, 95% CI 1.03-1.82), readmission < 30 days (OR 1.36, 95% CI 1.11-1.68), major adverse cardiac events (OR 1.59, 95% CI 1.09-2.32), respiratory complications (OR 1.47, 95% CI 1.16-1.88) and renal failure (OR 1.57, 95% CI 1.16-2.11). CONCLUSION: Endovascular aneurysm repair with adjunctive stenting (EVAR-S) was associated with vascular complications requiring reintervention, although the overall rate was very low. As well, readmission within 30 days, cardiac complications, respiratory problems and renal failure were more likely when compared to standard EVAR. The need for adjunctive stenting acts as a marker for an overall sicker and more complex population, not just in terms of vascular complications but across all medical complications as well. Staging the procedure may be helpful in terms of spreading out the operative risk into smaller portions. Furthermore, consideration of a non-operative strategy should be discussed with the patient if the risk of the procedure outweighs the risk of aneurysm rupture in high-risk groups.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Foreman T, Bitar A, Smith JB, et al. Outcomes of Endovascular Aneurysm Repair with Adjunctive Stenting. Ann Vasc Surg. 2021. PMID: 34687886. doi:10.1016/j.avsg.2021.08.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。